XM无法为美国居民提供服务。

EyePoint slides after unveiling $100 mln stock offering



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BUZZ-EyePoint slides after unveiling $100 mln stock offering</title></head><body>

Updates

** Shares of EyePoint Pharmaceuticals EYPT.O slide 8.5% to $11.09 after the bell

** EYPTunveils public offering of $100 mln worth of shares

** J.P. Morgan, Citigroup and Guggenheim Securities are the joint book running managers for the offering

** EYPT stock closed up 27.6% at $12.12 on Monday

** Co has 53.5 mln outstanding shares, giving it a $648.6 mln market capitalization - LSEG data

** Earlier in the day, EYPT saidits drug, Duravyu, showed an improvement in how well patients can see objects at a distance in a mid-stage trial testing it in diabetic macular edema (DME)

** EYPT plans on using the proceeds to advance the development of Duravyu as well as support its earlier stage pipeline development initiatives

** DME is an eye condition that causes blurry vision in people with diabetes

** EYPT expectsto report the full topline results in Q1 2025

** As of last close,EYPT stock down 47.6% YTD



Reporting by Puyaan Singh and Arasu Kannagi Basil in Bengaluru

</body></html>

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明